Concepedia

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma

Martina Sanlorenzo, Aditi Choudhry, Igor Vujic, Christian Posch, Chong Ae Kim, Katia Johnston, Melissa M. Meier, Simona Osella‐Abate, Pietro Quaglino, Adil Daud,

Journal of the American Academy of Dermatology · 2014 · 78 citations · 22 references

DOIFull text

Open access

Concepts

References

22

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text

, , +9

Final Version of 2009 AJCC Melanoma Staging and Classification

Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology · 2009 · 4.6K citations · Full text

, , +17

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations

, , +17

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations

, , +11

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

, , +16